Eterna Therapeutics Stock Net Income

ERNA Stock  USD 0.29  0.03  9.38%   
Eterna Therapeutics fundamentals help investors to digest information that contributes to Eterna Therapeutics' financial success or failures. It also enables traders to predict the movement of Eterna Stock. The fundamental analysis module provides a way to measure Eterna Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eterna Therapeutics stock.
Last ReportedProjected for Next Year
Net Loss-21.7 M-22.8 M
Net Loss-22.1 M-21 M
Net Loss-20 M-21 M
Net Loss(4.08)(4.28)
Net Income Per E B T 1.00  0.77 
As of December 14, 2024, Net Loss is expected to decline to about (22.8 M). The current year's Net Loss is expected to grow to about (21 M).
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Eterna Therapeutics Company Net Income Analysis

Eterna Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current Eterna Therapeutics Net Income

    
  (21.67 M)  
Most of Eterna Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eterna Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Eterna Net Income Driver Correlations

Understanding the fundamental principles of building solid financial models for Eterna Therapeutics is extremely important. It helps to project a fair market value of Eterna Stock properly, considering its historical fundamentals such as Net Income. Since Eterna Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eterna Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eterna Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Eterna Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

(855)

At present, Eterna Therapeutics' Accumulated Other Comprehensive Income is projected to decrease significantly based on the last few years of reporting.
Based on the recorded statements, Eterna Therapeutics reported net income of (21.67 Million). This is 106.35% lower than that of the Biotechnology sector and 130.93% lower than that of the Health Care industry. The net income for all United States stocks is 103.79% higher than that of the company.

Eterna Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eterna Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eterna Therapeutics could also be used in its relative valuation, which is a method of valuing Eterna Therapeutics by comparing valuation metrics of similar companies.
Eterna Therapeutics is currently under evaluation in net income category among its peers.

Eterna Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in Eterna Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Eterna Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eterna Therapeutics' value.
Shares
Tower Research Capital Llc2024-09-30
K
A. Montag & Associates Inc2024-06-30
212
Bank Of America Corp2024-09-30
123
Morgan Stanley - Brokerage Accounts2024-09-30
50.0
Activest Wealth Management2024-09-30
50.0
Royal Bank Of Canada2024-06-30
22.0
Group One Trading, Lp2024-09-30
19.0
Citigroup Inc2024-09-30
15.0
Jpmorgan Chase & Co2024-09-30
14.0
Ci Private Wealth Llc2024-09-30
262.9 K
Cypress Point Wealth Management, Llc2024-09-30
94.4 K

Eterna Fundamentals

About Eterna Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Eterna Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eterna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eterna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:
Check out Eterna Therapeutics Piotroski F Score and Eterna Therapeutics Altman Z Score analysis.
For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.31)
Revenue Per Share
0.03
Return On Assets
(0.29)
Return On Equity
(11.54)
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.